Quantum Stocks (IonQ, Rigetti, D-Wave, Quantum Computing Inc) Surge 700–6,000% – Bubble or Breakthrough? (Oct. 13, 2025)

Quantum Stocks (IonQ, Rigetti, D-Wave, Quantum Computing Inc) Surge 700–6,000% – Bubble or Breakthrough? (Oct. 13, 2025)

  • Quantum mania reaches fever pitch. Pure-play quantum companies IonQ (NYSE: IONQ), Rigetti (NASDAQ: RGTI), D-Wave (NYSE: QBTS) and Quantum Computing Inc (NASDAQ: QUBT) have soared several-fold in 2025, e.g. Rigetti is up ~4,000% year-over-year ts2.tech ts2.tech and IonQ ~700% ts2.tech. D-Wave and others have also run up strongly (D-Wave ~+2000% YOY ts2.tech). By mid-October 2025, IonQ traded near ~$73–75 (an all-time high) ts2.tech, Rigetti around $47 ts2.tech, D-Wave about $33, and QUBT ~$24 (all vastly above their 2024 prices).
  • Weak fundamentals, big valuations. None of these pure-play quantum firms is yet profitable: annual revenues are in the single-digit millions ts2.tech ts2.tech while market caps run into the tens of billions. Barron’s warns that the quartet of Rigetti, IonQ, D-Wave and QUBT has risen nearly 4× on average in a year, “even though they generate relatively little revenue” Tipranks ts2.tech. McKinsey’s 2035 forecast (quantum could grow from ~$1 B today to $72 B) suggests long-term promise, but experts caution current valuations outstrip fundamentals ts2.tech ts2.tech.
  • Recent corporate catalysts. In late Sept/early Oct, all three pure-plays hit new highs amid fresh announcements. Rigetti won ~$5.7 M in Novera orders and a $5.8 M U.S. Air Force quantum networking contract ts2.tech, while unveiling a 36-qubit “Cepheus” processor and partnerships (e.g. a $100M+ collaboration with Quanta, and an India R&D MOU) ts2.tech ts2.tech. IonQ inked deals and made bold acquisitions (e.g. a $1.08 B deal to buy Oxford Ionics and smaller buys of Vector Atomic, Lightsynq, Capella) ts2.tech ts2.tech. On Oct 7, IonQ also announced a strategic investment in Swedish trucking startup Einride (integrating quantum optimization), which sent IONQ shares up ~10% ts2.tech【52†[16]】. Quantum Computing Inc. (QUBT) surged after announcing a $750 M equity raise (oversubscribed private placement) and unveiling a photonic quantum encryption prototype ts2.tech ts2.tech. On the same day QUBT’s stock plunged 11% (on dilution fears) before rebounding with the sector’s rally ts2.tech.
  • Expert caution: “pure speculation.” The headlong rush has drawn warnings. CNBC’s Jim Cramer warned Rigetti is “pure speculation” – “I don’t know whether [it] is worth what it’s trading at” ts2.tech. A Barron’s column similarly cautioned that quantum names have surged ~4× despite “limited” commercial use, and that this “bubble may keep inflating until it is tested by fundamentals” Tipranks ts2.tech. Morgan Stanley analyst Joseph Moore even projects potential plunges: he sees up to ~60% drops for both IonQ and Rigetti if sentiment reverses Sharewise. Other strategists sound ambivalence – one Bank of America strategist hailed quantum as “the most important technological race of our generation,” yet many analysts still peg quantum stocks as high-risk “lottery ticket” plays ts2.tech.
  • Analyst ratings & price targets. Wall Street is divided. All covering analysts rate Rigetti a Buy or Strong Buy, but their price targets (~$20–24) lie well below the current $47 level ts2.tech, implying ~50% downside. (Exceptions: Benchmark recently raised RGTI to $50, B. Riley $35 ts2.tech.) IonQ’s consensus 12-month target (~$58) suggests downside from ~$75 ts2.tech, though Needham and B. Riley have targets of $80–$100 ts2.tech. TipRanks highlights other quantum plays: analysts see 20%+ upside in Quantum Computing Inc (QUBT, avg target $32 ≈ +64%) and even in diversified names with quantum exposure – Honeywell (its Quantinuum unit raised $600M, HON target +24%) and Microsoft (MSFT target +23%) Tipranks Tipranks. In sum, bulls tout huge growth potential (even Barron’s noted QUBT “could rise 86%” more ts2.tech), while bears point to sky-high P/S ratios and tiny sales (QUBT had just $61K revenue in Q2 against a multi-$B valuation ts2.tech).
  • Big-tech context & forecasts. Tech giants and governments are doubling down on quantum: IBM, Google (Alphabet), Microsoft, Intel and Amazon all pour billions into R&D. IBM’s stock itself has rallied to multi-year highs (~$280) after unveiling a quantum breakthrough and new AI deals ts2.tech. Major forecasts still see quantum as a long-term winner: McKinsey (among others) expects market size to grow from ~$1 B today to ~$72 B by 2035 ts2.tech ts2.tech (BCC Research even projects over $1 trillion in economic impact). But such projections assume quantum computing achieves true scale in the 2030s. For now the sector’s “boom” is fueled largely by speculative mania, as reflected in charts and valuations.

In short: The quantum wave shows no signs of cresting – stocks like IonQ, Rigetti and QUBT continue to race higher on every piece of news. Current share prices, however, embed aggressive future growth that isn’t yet realized. As one commentator put it, many investors are “buying a vision of the future” ts2.tech. The coming months will test whether these parabolic runs are the start of a historic tech breakout or the peak of a frothy bubble. (All data as of mid-October 2025.)

Sources: Recent Barron’s/TipRanks reports Tipranks ts2.tech, TipRanks analyses Tipranks Tipranks, and TechStock² (TS2.tech) deep-dives on IonQ, Rigetti, QUBT and others ts2.tech ts2.tech ts2.tech. These include expert quotes, SEC filings and up-to-date stock statistics.

A technology and finance expert writing for TS2.tech. He analyzes developments in satellites, telecommunications, and artificial intelligence, with a focus on their impact on global markets. Author of industry reports and market commentary, often cited in tech and business media. Passionate about innovation and the digital economy.

Stock Market Today

  • Kyowa Kirin Shares Appear Undervalued After Recent Price Dip
    January 31, 2026, 8:41 AM EST. Kyowa Kirin's stock closed at ¥2,504.5 with a 5.4% drop over the past week, reflecting cautious investor sentiment amid its pharmaceutical pipeline updates. Despite this, a discounted cash flow (DCF) model values the stock at ¥5,289.1 per share, indicating a 52.6% undervaluation against its current price. The DCF forecast is based on free cash flow projections rising from ¥2.7 billion to over ¥73 billion by 2029, discounted back to present value for intrinsic worth assessment. While the stock shows mixed performance over multiple timeframes, this valuation suggests potential upside. Investors should weigh market volatility and sector dynamics when considering Kyowa Kirin's investment prospects in pharmaceuticals and biotech.
QuantumScape Rockets 200% on Solid-State Battery Breakthrough – Revolution or Reckoning?
Previous Story

QuantumScape Rockets 200% on Solid-State Battery Breakthrough – Revolution or Reckoning?

BLS International Faces Govt Ban: Shares Plunge 18% – Analysts See 100% Upside?
Next Story

BLS International Faces Govt Ban: Shares Plunge 18% – Analysts See 100% Upside?

Go toTop